News
UTHR
593.31
-0.39%
-2.35
Here's How Much $100 Invested In United Therapeutics 15 Years Ago Would Be Worth Today
Benzinga · 1h ago
What United Therapeutics Holders Bought Into
Simply Wall St · 23h ago
Liquidia extends gains as Raymond James upgrades on Yutrepia launch
Seeking Alpha · 1d ago
Nvidia downgraded, Mercury Systems upgraded: Wall Street’s top analyst calls
TipRanks · 1d ago
Liquidia price target raised to $66 from $58 at Needham
TipRanks · 2d ago
Liquidia price target raised to $87 from $70 at BTIG
TipRanks · 2d ago
United Therapeutics (UTHR) Stock Still Looks Like A Bargain As Its 184% Run Continues
Simply Wall St · 2d ago
DraftKings downgraded, AMD upgraded: Wall Street’s top analyst calls
TipRanks · 3d ago
United Therapeutics Price Target Announced at $660.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
United Therapeutics Coverage Assumed by HC Wainwright & Co. at Buy
Dow Jones · 3d ago
HC Wainwright & Co. Assumes United Therapeutics at Buy, Announces Price Target of $660
Benzinga · 3d ago
United Therapeutics assumed with a Buy at H.C. Wainwright
TipRanks · 3d ago
Weekly Report: what happened at UTHR last week (1102-1106)?
Weekly Report · 3d ago
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
Barchart · 3d ago
Is United Therapeutics (UTHR) Undervalued On Earnings And Its $2b Buyback?
Simply Wall St · 5d ago
The 5 most interesting analyst questions from United Therapeutics’s Q3 2026 earnings call
Barchart · 6d ago
United Therapeutics Is Maintained at Buy by TD Cowen
Dow Jones · 11/05 20:44
TD Cowen Maintains Buy on United Therapeutics, Raises Price Target to $700
Benzinga · 11/05 20:39
United Therapeutics Price Target Raised to $725.00/Share From $697.00 by RBC Capital
Dow Jones · 11/05 20:16
United Therapeutics Is Maintained at Outperform by RBC Capital
Dow Jones · 11/05 20:16
More
Webull provides a variety of real-time UTHR stock news. You can receive the latest news about United Therapeutics Corp. through multiple platforms. This information may help you make smarter investment decisions.
About UTHR
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia.